HemaSphere (Jun 2022)
P958: REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSES FROM THE LOCOMMOTION STUDY
- H. Einsele,
- P. Moreau,
- V. De Stefano,
- D. Dytfeld,
- E. Angelucci,
- R. Benjamin,
- H. Goldschmidt,
- N. W. van de Donk,
- B. Besemer,
- C. Scheid,
- R. Vij,
- E. I. ’. Groen-Damen,
- M. Semerjian,
- V. Strulev,
- J. M. Schecter,
- T. Roccia,
- T. Nesheiwat,
- R. Wapenaar,
- K. Weisel,
- M.-V. Mateos
Affiliations
- H. Einsele
- 1 Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany
- P. Moreau
- 2 University Hospital Hôtel-Dieu, Nantes, France
- V. De Stefano
- 3 Section of Hematology, Catholic University, Fondazione Policlinico A Gemelli, IRCCS, Rome, Italy
- D. Dytfeld
- 4 Poznań University of Medical Sciences, Poznań, Poland
- E. Angelucci
- 5 Hematology and Transplant Center, IRCCS Ospedale Policlinico San Martino, Genova, Italy
- R. Benjamin
- 6 Department of Haematology, King’s College Hospital, London and School of Cancer and Pharmaceutical Sciences, King’s College, London, United Kingdom
- H. Goldschmidt
- 7 University Hospital Heidelberg, Heidelberg, Germany
- N. W. van de Donk
- 8 Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
- B. Besemer
- 9 University Hospital Tubingen, Tubingen, Germany
- C. Scheid
- 10 University of Cologne, Cologne, Germany
- R. Vij
- 11 Washington University School of Medicine, St. Louis, MO, United States of America
- E. I. ’. Groen-Damen
- 12 Janssen-Cilag, Breda, Netherlands
- M. Semerjian
- 13 Janssen-Cilag, Issy-Les-Moulineaux, France
- V. Strulev
- 14 Janssen Pharmaceutica NV, Beerse, Belgium
- J. M. Schecter
- 15 Janssen R&D, Raritan, NJ, United States of America
- T. Roccia
- 16 Janssen R&D, High Wycombe, United Kingdom
- T. Nesheiwat
- 17 Legend Biotech USA, Piscataway, NJ, United States of America
- R. Wapenaar
- 12 Janssen-Cilag, Breda, Netherlands
- K. Weisel
- 18 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- M.-V. Mateos
- 19 University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain
- DOI
- https://doi.org/10.1097/01.HS9.0000846700.91803.1a
- Journal volume & issue
-
Vol. 6
pp. 848 – 849
Abstract
No abstracts available.